Timing of Estradiol Treatment After Menopause May Determine Benefit or Harm to Insulin Action | Zendy

Rocio I. Pereira | Zendy; Beret A. Casey | Zendy; Tracy A. Swibas | Zendy; Christopher Erickson | Zendy; Pamela Wolfe | Zendy; Rachael E. Van Pelt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Timing of Estradiol Treatment After Menopause May Determine Benefit or Harm to Insulin Action

Author(s) -

Rocio I. Pereira,

Beret A. Casey,

Tracy A. Swibas,

Christopher Erickson,

Pamela Wolfe,

Rachael E. Van Pelt

Publication year - 2015

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2015-3084

Subject(s) - medicine , menopause , endocrinology , insulin , placebo , estrogen , transdermal , body mass index , type 2 diabetes , crossover study , insulin resistance , diabetes mellitus , pharmacology , alternative medicine , pathology

Type 2 diabetes (T2D) is reduced in postmenopausal women randomized to estrogen-based hormone therapy (HT) compared with placebo. Insulin sensitivity is a key determinant of T2D risk and overall cardiometabolic health, and studies indicate that estradiol (E2) directly impacts insulin action.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research